Immunotherapy for pancreatic cancer: Current concepts

Hematology/Oncology Clinics of North America

Volumn 16, Issue 1, 2002, Pages 159-197

  Kaufman, Howard L ^a   Di Vito, Joseph ^a   Hörig, Heidi ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BACTERIAL VACCINE; BCG VACCINE; CANCER VACCINE; CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MUCIN; ONCOPROTEIN; SALMONELLOSIS VACCINE; SYNTHETIC PEPTIDE; TRASTUZUMAB; TUMOR ANTIGEN; UNINDEXED DRUG; VIRUS VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DENDRITIC CELL; DNA MICROARRAY; DRUG DELIVERY SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MELANOMA; NONHUMAN; PANCREAS CANCER; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; CYTOKINES; DENDRITIC CELLS; FORECASTING; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; PANCREATIC NEOPLASMS; T-LYMPHOCYTE SUBSETS; TUMOR ESCAPE; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 0036258998     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(01)00002-8     Document Type: Review

References (179)

1. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2)
2. Generation of stable CD4 and CD8T-cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations
3. Dendritic cells acquire antigen from apoptotic cells and induce class 1-restricted CTLs
4. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire
5. Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice
6. Superantigen-targeted therapy: Phase escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies
7. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: Evidence for multistep carcinogenesis
8. The use of rapid ELISPOT assay to analyze peptide specific immune responses in carcinoma patients to peptide vs. Recombinant poxvirus vaccines
9. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino not carboxyl-terminus of the peptide
10. Imaging of pancreatic and colorectal cancer using antibody fragments: A preliminary evaluation
11. Dendritic cells and the control of immunity
12. Immunization of chimpanzees with tumor antigen MUCI mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses
13. Mucosal immunization with HIV-peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge
14. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
15. Identification of a human CD8T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele
16. HLA binding characteristics and generation of cytotoxic lymphocytes against peptides derived from oncogenic proteins
17. Minor H antigens introduced on 11-2 different stimulating cells cross-react at the cytotoxic T-cell level during in vivo priming
18. Molecular classification of cutaneous malignant melanoma by gene expression profiling
19. A phase pilot trial of 13-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma
20. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
21. The immunological synapse
22. Presentation of exogenous protein antigens on major histocompatibility complex class molecules by dendritic cells: Pathway of presentation and regulation by cytokines
23. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
24. On the cellular basis of immunological T-cell memory
25. p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer
26. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis
27. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes
28. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes
29. The expanding world of co-stimulation: The two-signal model revisited
30. Phase clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound-guided fine-needle injection in patients with advanced pancreatic carcinoma
31. CD4+ T-cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
32. Phase study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge
33. A report of recent cases of inoperable sarcoma successfully treated with mixed toxins of rysipelas and Bacillus prodigiosus
34. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine
35. Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen
36. Transfer of specificity for human immunodeficiency virus type into primary human T lymphocytes by introduction of T-cell receptor genes
37. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
38. Identification of a peptide recognized by five melanoma-specific human cytotoxic T-cell lines
39. The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T-cell function
40. Immunohistochemical evaluation of HER 2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms
41. Effects of SV40 virus immunization on growth of transplantable SV40 and polyoma virus tumors in hamsters
42. HER-2/neu expression in pancreatic adenocarcinoma: Relation to tumor differentiation and survival
43. Structure of peptides associated with class I and class II MHC molecules
44. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen
45. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
46. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine
47. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice
48. Clinical effects of monoclonal antibodies (MAb 17-IA) in patients with metastatic colorectal carcinomas
49. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation
50. Gene therapy with Adv-IL-2 in unresectable digestive cancer: Phase I-II study, intermediate report
51. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study
52. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation
53. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma
54. Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption technique
55. The epithelial cell surface antigen 17-IA. A target for antibody-mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies
56. A phase I trial of a synthetic mucin peptide vaccine: Induction of specific immune reactivity in patients with adenocarcinoma
57. Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy
58. Adoptive T-cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
59. Cancer statistics, 2000
60. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line
61. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas
62. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
63. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer
64. Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions: A comparison with CA 50 and CA 19-9
65. Decrease of CA 19 9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
66. Eradication of established tumors by CD8 T-cell adoptive immunotherapy
67. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283
68. CA19 9: A predictor of response in pancreatic cancer treated with gemcitabine and cisplatin
69. Cell-mediated immunity against antigens common to human colonic carcinomas and fetal gut epithelium
70. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4 T-cells
71. Presentation of MUC1 tumor antigen by class 1 MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells
72. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian poxvirus to enhance T-cell immunity and antitumor responses
73. Enhanced activation of T-cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules
74. A triad of costimulatory molecules synergize to amplify T-cell activation
75. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-Year median follow-up of a phase III prospectively randomized trial
76. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer
77. Current issues in cancer vaccine development
78. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule
79. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T-cells and NK cells
80. K-ras oncogene activation in adenocarcinoma of the human pancreas: A study of82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization
81. Role of bone marrow-derived cells in presenting MHC class 1-restricted tumor antigens
82. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade
83. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL
84. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
85. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials
86. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma
87. Tumor-specific cytotoxic T-cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA
88. Immunocytological detection of micrometastatic cells: Comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients
89. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer
90. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination
91. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine
92. A phase I trial of intralesional RV-B7.1 vaccine in the treatment of malignant melanoma
93. A phase I trial of intralesional rV-TRICOM vaccine in the treatment of malignant melanoma
94. Identification of tumor-regression antigens in melanoma
95. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
96. Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A(*)0201 binding affinity
97. Loss of tumorigenicity of human pancreatic carcinoma cells engineered to produce interleukin-2 or interleukin-4 in nude mice: A potentiality for cancer gene therapy
98. Acquired immunity in nude mice induced by expression of the Il-2 or IL-4 gene in human pancreatic carcinoma cells and anti-tumor effect generated by in vivo gene transfer using retrovirus
99. Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer
100. Continuous culture of fused cells secreting antibodies of predefined specificity
101. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma
102. Comparison of a new tumour marker CA 242 with CA 19 9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases
103. Characterization of circulating T-cells specific for tumor associated antigens in melanoma patients
104. Development of cancer vaccines using recombinant BCG expressing human CEA
105. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes
106. Fax and FasL in the homeostatic regulation of immune responses
107. The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T-cells
108. Identification of T helper epitodes from prostatic acid phosphatase
109. Phase I study in cancer patients of a replication defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
110. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
111. Phase I trial to determine the toxicity and immunologie efficacy of the addition of GM-CSF (GM) and IL-2 to the combination of vaccinia-CEA (V) and Alvac-CEA (A) administered as a prime and boost in patients (pts) with advanced CEA-bearing cancers
112. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine live attenuated oral poliovirus vaccine immunization schedules
113. Comparison of p53 protein expression and cellular localization in human and hamster pancreatic cancer cell lines
114. Differential MUC 1 expression in normal and neoplastic human pancreatic tissue: An immunohistochemical study of 60 samples
115. A phase 1 study of active immunotheraphy with carcinoembryonic antigen petide (CAP-1)-pulsed, autologous human cultured dentritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
116. Two types of murine helper T-cell clone: 1. Definition according to profiles of lymphokine activities and secreted proteins
117. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
118. Effective effective gene theraphy for pancreatic cancer by cytokines mediated by restricted replieation-competent adenovirus
119. CD4(+) T-cells eliminate MHC class II-negative cacer cells in vivo by indirect effects of IFN-gamma
120. Characterization of in vivo primary and secondary CD8- T-cell responses induced by recombinant influenza and vaccinia viruses
121. Induction of primary carcinoembryonic antigen (CEA) specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
122. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
123. Status of activation of circulating vaccine-elicited CD8+ T-cells
124. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients
125. Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer
126. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte
127. Interferon-based adjuvant chemoradiation therapy improves Survival after pancreaticoduodenectomy for pancreatic adenocarcinoma
128. Immune surveillance against a solid tumor fails because of immunological ignorance
129. Applications of pox virus vectors to vaccination: An update
130. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes
131. Immunity to methylcholanthrene-induced sarcomas
132. CD4+ T-cell mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells
133. MHC ligands and peptide motifs: First listing
134. Lymphokine-activated killer (LAK) cell phenomenon: Analysis of factors relevant to the immunotherapy of human cancers
135. A listing of human tumor antigens recognized by T-cells
136. Molecular mechanisms used by tumors to escape immune recognition: Immunogenetherapy and the cell biology of major histocompatibility complex class I
137. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
138. A mutated beta-catenin gene encodes a melanomaspecific antigen recognize by tumor infiltrating lymphocytes
139. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
140. Pancreatic cancer: A review of emerging therapies
141. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
142. Lysosome-associated membrane protein-I mediated targeting of the IIIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T-cells
143. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
144. p53 protein expression as prognostic factor in human pancreatic cancer
145. Phase 1/11 trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma
146. Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer
147. CaSm: An Sm-like protein that contributes to the transformed state in cancer cells
148. Antigen-processing machinery breakdown and tumor growth
149. Association between CEA-specific T-cell responses [TCR) following treatment with vaccinia-CEA (V) and Alvac-CEA (A) and survival in patients (Pts) with CEA-bearing cancers
150. Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world
151. The clinical utility of the CA 19 9 tumor-associated antigen
152. Identification of a novel cell type in peripheral lymphoid organs of mice: I.V. Identification and distribution in mouse spleen
153. Production of monoclonal antibodies to serum antigens in colorectal carcinoma
154. Expression of mucin carbohydrate antigens (T, Tn and sialyl Tn) and MUC-1 gene product in intraductal papillary-mucinous neoplasm of the pancreas
155. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives
156. CD4 T-cells and their role in antitumor immune responses
157. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
158. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia CEA vaccine
159. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: Antigen presentation by non-muscle cells
160. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
161. The influence of granulocyte-macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA-B7.1) in patients with metastatic carcinoma
162. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas
163. Phase 11/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract
164. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back
165. High-fidelity mRNA amplification for gene profiling
166. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice
167. Radioimmunotherapy of orthotopically transplanted pancreatic cancer with 1311-labeled chimeric monoclonal antibody Nd2
168. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
169. Mechanisms of exogenous antigen presentation by MHC class 1 molecules in vitro and in vivo: Implications for generating CD8+ T-cell responses to infections agents, tumors, transplants, and vaccines
170. MUC-1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas
171. Antitumor effect of human pancreatic cancer cells transduced with cytokine genes which activate Th1 helper T-cells
172. Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene
173. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: Influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics
174. The rol of B7 CD28 co-stimulation in tumor rejection
175. Hepatitis B vaccine: Current issues
176. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine
177. Localization dose and time of antigens determine immune reactivity
178. On immunological memory